Changes/additions to materials:

29th March 2010: NICE has reissued its guideline on cardiovascular risk assessment and lipid modification (CG67) removing the recommendation to use a specific method for risk estimation (based on the Framingham equation).  NICE considered new evidence relating to QRISK but concluded that it was not able to recommend one cardiovascular risk estimation method over another. It has therefore left the decision to the NHS locally to use the method best suited to their requirements. All other recommendations in the guideline are unchanged. 

NICE update guidance on type 2 diabetes
In May 2009, since these materials were published on NPCi, NICE issued a partial update to their previous clinical guideline on type 2 diabetes, which was published in May 2008. The unchanged recommendations have been combined with specific new recommendations about blood glucose control with sitagliptin▼, vildagliptin▼, pioglitazone▼, rosiglitazone, exenatide▼ and insulin therapy. The update is summarised in a blog.

Changes to reporting of HbA1c
The Department of Health have announced that, from 1st June 2009, glycated haemoglobin (HbA1c) will be measured in millimoles per mol (mmol/mol) as well as by percentage (%) in all people with diabetes. Measurements will be reported in both ways until 31 May 2011 when people with diabetes will receive their HbA1c measurement only in millimoles per mol. See blog for more information.

Case study 1: initial management of type 2 diabetes

Ted, a 56-year old salesman with symptoms of diabetes

Case study 2: ongoing management of type 2 diabetes

Ted, now found to have raised blood pressure 2 months after being diagnosed with type 2 diabetes

Case study 3: prevention of type 2 diabetes

Carol, a 54-year old woman who is worried that she is at risk of developing type-2 diabetes